COVID-related fibrosis: insights into potential drug targets.
Expert Opin Investig Drugs
; 30(12): 1183-1195, 2021 Dec.
Статья
в английский
| MEDLINE | ID: covidwho-1541410
ABSTRACT
INTRODUCTION:
Lung injury in severe COVID-19 pneumonia can rapidly evolve to established pulmonary fibrosis, with prognostic implications in the acute phase of the disease and long-lasting impact on the quality of life of COVID-19 survivors. This is an emerging medical need, and it has been hypothesized that antifibrotic treatments could have a role in ameliorating the fibrotic process in the lungs of these patients. AREAS COVERED The safety and efficacy of available antifibrotic drugs (nintedanib and pirfenidone) and novel promising agents are being assessed in several ongoing clinical trials that were performed either in critically ill patients admitted to intensive care, or in discharged patients presenting fibrotic sequalae from COVID-19. Literature search was performed using Medline and Clinicaltrials.org databases (2001-2021). EXPERT OPINION Despite the strong rationale support the use of antifibrotic therapies in COVID-related fibrosis, there are several uncertainties regarding the timing for their introduction and the real risks/benefits ratio of antifibrotic treatment in the acute and the chronic phases of the disease. The findings of ongoing clinical trials and the long-term observation of longitudinal cohorts will eventually clarify the best management approach for these patients.ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Pulmonary Fibrosis
/
COVID-19
/
Antifibrotic Agents
Тип исследования:
Когортное исследование
/
Наблюдательное исследование
/
Прогностическое исследование
/
Отзывы
Темы:
Длинный Ковид
Пределы темы:
Животные
/
Люди
Язык:
английский
Журнал:
Expert Opin Investig Drugs
Тематика журнала:
Лекарственная терапия
Год:
2021
Тип:
Статья
Аффилированная страна:
13543784.2021.2010188
Документы, близкие по теме
MEDLINE
...
LILACS
LIS